Skip to main content
. 2015 Apr 5;5(7):746–754. doi: 10.7150/thno.10732

Fig 4.

Fig 4

In vivo tumor uptake of four liposomes in U87MG xenograft and SCC-7 allograft models. (a) Rhodamine-labeled liposomes were intravenously injected into two U87MG xenograft and SCC-7 allograft tumor-bearing mice via tail veins. After 24 h, mice were euthanized and tumors were excised and viewed with IVIS imaging system. The highest uptake was seen in both APTEDB-PEG2000/PEG1000 LS and APTEDB-PEG1000/PEG550 LS treated groups. (n=2 for each group for each cell line, s.e.) (b) In vivo anti-tumor efficacy was assessed in U87MG xenograft model. After treatment of Dox-encapsulated APTEDB-PEG2000/PEG2000 LS, APTEDB-PEG2000/PEG1000 LS, APTEDB-PEG1000/PEG1000 LS and APTEDB-PEG1000/PEG550 LS at a dose of 2 mg Dox/kg, tumor was excised; and the tumor size and weight were measured. The greatest suppression of tumor growth was achieved in APTEDB-PEG2000/PEG1000 LS (Dox) (~90%), followed by APTEDB-PEG1000/PEG550 LS (Dox) (~80%), while non-targeting LS and free Dox showed modest anti-tumor efficacy of ~28% and ~65%, respectively. Statistical analysis was carried out with Students' T Test, with *p value < 0.01 for APTEDB-PEG2000/PEG2000 LS and APTEDB-PEG1000/PEG1000 LS; **p value < 0.001 for APTEDB-PEG2000/PEG1000 LS, APTEDB-PEG1000/PEG550 LS as compared to control group.